Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 7/20 | 0.51 |
| ▸ | NT5E | P21589 | 9/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CDK4 | P11802 | 4/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.41 |
| ▸ | CCND1 | P24385 | 4/20 | 0.41 |
| ▸ | CDK7 | P50613 | 4/20 | 0.41 |
| ▸ | CCNH | P51946 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24026343 | 0.84 | NT5E (0.55) | CDK1NT5ECDK5 | |
| SCHEMBL20350737 | 0.82 | NT5E (0.49) | NT5E | |
| SCHEMBL22216669 | 0.82 | NT5E (0.49) | NT5E | |
| SCHEMBL20350816 | 0.81 | NT5E (0.50) | NT5E | |
| SCHEMBL24835577 | 0.81 | NT5E (0.49) | NT5E | |
| SCHEMBL22215137 | 0.80 | CDK1 (0.57) | CDK1NT5ECDK5CDK2KDM4E | |
| SCHEMBL21602048 | 0.75 | NT5E (0.46) | CDK1NT5E | |
| SCHEMBL24026326 | 0.75 | NT5E (0.45) | NT5E | |
| SCHEMBL20333416 | 0.75 | NT5E (0.73) | NT5EADORA3ADORA1 | |
| SCHEMBL24026246 | 0.75 | NT5E (0.59) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CDK1 2642/4885NT5E 1/4885CDK5 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.